transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Significant reduction in body fat assessed by echomri in subjects treated with orlistat 60 mg for 6 months compared with placebo: relationships between changes in body composition and body weight

Författare och institution:
Kaj Stenlöf (Institutionen för medicin, avdelningen för klinisk prövning och entreprenörskap); F Greenway (-); SR Smith (-); K Murray (-); J McHutchison (-); V Agarwal (-); S Schwartz (-); TH Bacon (-)
Publicerad i:
Obesity Reviews (Poster presentations), 11 ( Supplement s1 ) s. 235
Konferensbidrag, refereegranskat
Sammanfattning (abstract):
Introduction: A randomised, double-blind study has demonstrated that orlistat 60 mg is significantly more effective than placebo in reducing visceral fat measured by CT (1). New data from this multicentre study are used to investigate associations between changes in body composition [EchoMRI, total fat mass; body impedance analysis (BIA), % body fat] and body weight. Methods: Adults (BMI 25–34.9 kg/m2) with a waist circumference >88 cm (women) or 102 cm (men) were randomised to receive orlistat 60 mg or placebo, 3x/day for 6 months. A reduced calorie, lower-fat diet was recommended and subjects were encouraged to exercise. Body fat was measured at baseline and weeks 2, 4, 12, and 24. Results: Demographic and baseline characteristics were similar between orlistat 60 mg (n = 62) and placebo (n = 61) groups. Conclusion: Orlistat 60 mg was significantly more effective than placebo in reducing body fat as assessed by EchoMRI and BIA. Change in total fat mass measured by EchoMRI was highly correlated with change in body weight, but the association with weight loss was less marked when measured by BIA (1). Orlistat 60 mg demonstrates a significant reduction in visceral adipose tissue at 24 weeks compared with placebo. Abstract presented at ICAO, Hong Kong, January 2010. Conflict of interest: Investigator, GlaxoSmithKline Consumer Healthcare.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Klinisk medicin ->
Dermatologi och venereologi
Klinisk medicin ->
Endokrinologi och diabetes ->
Postens nummer:
Posten skapad:
2011-01-20 14:20
Posten ändrad:
2012-02-06 09:50

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007